Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Cervical Cancer: Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Cervical Cancer

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Melanoma: Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Melanoma

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Solid Tumor: Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Solid Tumor

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Non-Small Cell Lung Cancer: Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Non-Small Cell Lung Cancer

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Metastatic Colorectal Cancer: Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Metastatic Colorectal Cancer

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

212Pb-DOTAM-GRPR1 by Orano Med for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - 212Pb-DOTAM-GRPR1 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)